表紙:医薬品原薬 (API) の世界市場 (~2025年):タイプ (革新薬・ジェネリック薬)・製造業者区分 (自社用・販売用)・合成区分 (合成・バイオ技術)・製品区分 (ワクチン・ホルモン)・医薬品区分 (OTC・Rx)・疾患区分 (糖尿病・癌・CVD)・地域別
市場調査レポート
商品コード
962875

医薬品原薬 (API) の世界市場 (~2025年):タイプ (革新薬・ジェネリック薬)・製造業者区分 (自社用・販売用)・合成区分 (合成・バイオ技術)・製品区分 (ワクチン・ホルモン)・医薬品区分 (OTC・Rx)・疾患区分 (糖尿病・癌・CVD)・地域別

Active Pharmaceutical Ingredient (API) Market by type (Innovative, generic), manufacturer (captive, merchant), synthesis (synthetic, biotech), product (vaccines, Hormones), drug (OTC, Rx), application (Diabetes, oncology, CVD)-Global Forecast to 2025

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 320 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.77円
医薬品原薬 (API) の世界市場 (~2025年):タイプ (革新薬・ジェネリック薬)・製造業者区分 (自社用・販売用)・合成区分 (合成・バイオ技術)・製品区分 (ワクチン・ホルモン)・医薬品区分 (OTC・Rx)・疾患区分 (糖尿病・癌・CVD)・地域別
出版日: 2020年09月30日
発行: MarketsandMarkets
ページ情報: 英文 320 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の医薬品原薬 (API) の市場規模は予測期間中5.8%のCAGRで推移し、2020年の1873億米ドルから、2025年には2483億米ドルの規模に成長すると予測されています。さまざまな治療分野での免疫グロブリン利用の増加、血漿収集および血漿収集センターの数の増加、高齢者人口の増加、呼吸器疾患およびα-1アンチトリプシン欠損症 (AATD) の有病率の増加などの要因が同市場の成長を推進しています。一方で、血漿製品の高コスト性、償還の限定性、組換え代替品の台頭などの要因が市場のさらなる成長の妨げとなる可能性があります。

合成タイプ別で見ると、合成APIの部門が2019年に最大のシェアを占める一方で、成長率ではバイオ技術APIの部門が予測期間中最大のCAGRを示すと予測されています。バイオ医薬品の需要の増加、バイオテクノロジーの進歩、モノクローナル抗体への需要の増加、人体に存在する天然の生物学的化合物との類似性などの要因が同部門の成長を牽引しています。

当レポートでは、世界の医薬品原薬 (API) の市場を調査し、市場の定義と概要、バリューチェーン、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、市場規模の推移・予測、製品タイプ・製造業者タイプ・合成区分・医薬品区分・疾患区分・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 促進要因
    • 制限
    • 市場機会
    • 課題
  • COVID-19の影響
  • バリューチェーン分析
  • サプライチェーン分析
  • エコシステムの分析

第6章 市場分析・予測:タイプ別

  • 革新的医薬品原薬
  • ジェネリック医薬品原薬

第7章 市場分析・予測:製造業者タイプ別

  • 自社用APIメーカー
  • 販売用APIメーカー

第8章 市場分析・予測:合成タイプ別

  • 合成API
  • バイオ技術API
    • タイプ別
    • 製品別
    • 発現システム別

第9章 市場分析・予測:医薬品タイプ別

  • 処方薬
  • OTC薬
  • 力価別

第10章 市場分析・予測:疾患区分別

  • 伝染病
  • 糖尿病
  • 心血管疾患
  • 疼痛管理
  • 呼吸器疾患
  • その他

第11章 市場分析・予測:地域・主要国別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ハンガリー
    • その他
  • アジア
    • 日本
    • 中国
    • インド
    • 韓国
    • その他
  • その他の地域
    • イスラエル
    • その他

第12章 競合情勢

  • 概要
  • 市場評価の枠組み
  • 競争状況・動向

第13章 企業評価マトリックス・企業プロファイル

  • 企業評価マトリックス:定義・調査手法
  • 企業評価マトリックス
  • 競合リーダーシップマッピング:中小企業
  • 企業ランキング
  • 企業プロファイル
    • PFIZER, INC.
    • NOVARTIS AG
    • SANOFI
    • BOEHRINGER INGELHEIM
    • BRISTOL-MYERS SQUIBB
    • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • ELI LILLY AND COMPANY
    • GLAXOSMITHKLINE PLC
    • MERCK & CO., INC.
    • MYLAN NV
    • ABBVIE INC.
    • F. HOFFMANN-LA ROCHE LTD.
    • ASTRAZENECA
    • DR. REDDY'S LABORATORIES LTD.
    • SUN PHARMACEUTICAL INDUSTRIES LTD.
    • CIPLA, INC.
    • API PHARMA TECH
    • BDR PHARMACEUTICALS INTERNATIONALS PVT. LTD.
    • SREEPATHI PHARMACEUTICALS LIMITED
    • SHILPA MEDICARE LIMITED

第14章 付録

目次
Product Code: PH 1262

The global active pharmaceutical ingredients market is projected to reach USD 248.3 billion by 2025 from USD 187.3 billion in 2020, at a CAGR of 5.8% during the forecast period. Growth in the active pharmaceutical ingredients market is primarily driven by factors such as growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), rising geriatric population, and the growing prevalence of respiratory diseases and alpha-1-antitrypsin deficiency (AATD). However, the high cost of plasma products, limited reimbursements, and the emergence of recombinant alternatives are expected to restrain the growth of this market to a certain extent during the forecast period.

"Biotech APIs segment is expected to grow at the highest CAGR during the forecast period"

On the basis of type of synthesis, the APIs market is categorized into synthetic APIs and biotech APIs. The synthetic APIs segment is estimated to account for the largest share in 2019. However, the biotech APIs segment is expected to grow at a higher rate over the forecast period. Factors such as growing demand of biotech drugs due to their specificity in action, advancements in biotechnology, increase in the demand for monoclonal antibodies and their similarity with the natural biological compounds found in the human body influence the growth of this segment.

"Monoclonal antibodies segment is expected to account for the largest share of the global APIs market, by product type."

Based on product, the biotech APIs market is segmented into monoclonal antibodies, hormones, cytokines, fusion proteins, therapeutic enzymes, vaccines and blood factors. In 2019, the monoclonal antibodies segment is estimated to account for the largest share of the APIs market. Large share of monoclonal antibodies is due to their rising application in oncology and other therapeutic areas, increase in number of FDA approvals for innovative biopharmaceutical products and increasing investments and technical advances in R&D for development of various novel products.

"North America will dominate the market during the forecast period."

Geographically, the active pharmaceutical ingredients market is segmented into North America, Europe, Asia, andRest of the World. In 2019, North America accounted for the largest share of the active pharmaceutical ingredients market, followed by Europe and the Asia. . The major factors driving the overall growth of the APIs market in this region include the growing prevalence of preventable chronic diseases, increasing government emphasis on generic drugs, escalating demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type - Tier 1: 37%, Tier 2: 22%, and Tier 3: 41%
  • By Designation - C-level: 25%, D-level: 20%, and Others: 55%
  • By Region - North America: 40%, Europe: 27%, Asia: 20%, and RoW: 13%

List of Companies Profiled in the Report:

  • Pfizer, Inc. (US)
  • Novartis Internationla AG (Switzerland)
  • Sanofi (France)
  • Boehringer Ingelheim (Germany)
  • Bristol-Myers Squibb (US)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Eli Lilly and Company (US)
  • GlaxoSmithKline plc (UK)
  • Merck & Co., Inc. (US)
  • Mylan N.V. (US)
  • AbbVie Inc. (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • AstraZeneca (UK)
  • Cipla, Inc. (India)
  • Dr. Reddy's Laboratories Ltd. (India)
  • Sun Pharmaceutical Industries Ltd. (India)
  • API Pharma Tech (India)
  • BDR Pharmaceuticals Internationals Pvt. Ltd. (India)
  • Sreepathi Pharmaceuticals Limited (India)
  • Shilpa Medicare Limited (India)

Research Coverage:

This report provides a detailed picture of the global active pharmaceutical ingredients market. It aims at estimating the size and future growth potential of the market across different segments, such as type, type of manufacturer, type of synthesis, type of drug, application and region.. The report also analyzes factors (such as drivers, restraints, and opportunities) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total active pharmaceutical ingredients market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on active pharmaceutical ingredients offered by the top 25 players in the active pharmaceutical ingredients market. The report analyses the active pharmaceutical ingredients market based on the type, type of manufacturer, type of synthesis, type of drug, application and region..
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various active pharmaceutical ingredients across key geographic regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the active pharmaceutical ingredients market.
  • Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the active pharmaceutical ingredients market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 MARKET SEGMENTATION
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY SOURCES
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY SOURCES
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key data from primary sources
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 5 MARKET SIZE ESTIMATION: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

    • FIGURE 7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020 VS. 2025 (USD BILLION)
    • FIGURE 8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2020 VS. 2025 (USD BILLION)
    • FIGURE 9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020 VS. 2025 (USD BILLION)
    • FIGURE 10 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020 VS. 2025 (USD BILLION)
    • FIGURE 11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020 VS. 2025 (USD BILLION)
    • FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

4 PREMIUM INSIGHTS

  • 4.1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET OVERVIEW
    • FIGURE 13 INCREASING INCIDENCE OF CHRONIC DISEASES AND GROWING IMPORTANCE OF GENERICS ARE THE KEY FACTORS DRIVING MARKET GROWTH
  • 4.2 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE & TYPE OF MANUFACTURER (2019)
    • FIGURE 14 INNOVATIVE APIS SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2019
  • 4.3 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 15 CHINA TO WITNESS THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing incidence of chronic diseases
      • 5.2.1.2 Technological advancements in API manufacturing
      • 5.2.1.3 Growing importance of generics
    • TABLE 1 INDICATIVE LIST OF DRUGS GOING GENERIC IN 2020
      • 5.2.1.4 Increasing uptake of biopharmaceuticals
    • TABLE 2 INDICATIVE LIST OF BIOLOGICS THAT GAINED REGULATORY APPROVAL IN THE US IN 2019
      • 5.2.1.5 Growing adoption of AI-based tools for drug discovery
      • 5.2.1.6 Adoption of organ-on-chip models in drug development
      • 5.2.1.7 Focus on precision medicine
      • 5.2.1.8 Investments in real-world evidence by pharmaceutical companies
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Unfavorable drug price control policies
      • 5.2.2.2 High manufacturing costs
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging biosimilars market
    • TABLE 3 INDICATIVE LIST OF BIOSIMILARS THAT GAINED REGULATORY APPROVAL IN THE US (2019-2020)
      • 5.2.3.2 Highly potent active pharmaceutical ingredients
      • 5.2.3.3 Emerging markets
      • 5.2.3.4 Emerging technologies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Increasing penetration of counterfeit drugs
  • 5.3 IMPACT OF COVID-19 ON THE MARKET
    • TABLE 4 INDICATIVE LIST OF COVID-19 THERAPEUTIC DRUGS IN THE PIPELINE (CLINICAL)
    • 5.3.1 COVID-19 DRUG R&D: KEY DEVELOPMENTS
    • 5.3.2 COVID-19 DRUG R&D: VACCINE PRODUCTION SCENARIO, BY COUNTRY
  • 5.4 VALUE CHAIN ANALYSIS
    • FIGURE 16 MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE
  • 5.5 SUPPLY CHAIN ANALYSIS
    • FIGURE 17 DIRECT DISTRIBUTION-STRATEGY PREFERRED BY PROMINENT COMPANIES
  • 5.6 ECOSYSTEM ANALYSIS OF THE PHARMACEUTICALS MARKET
    • FIGURE 18 ECOSYSTEM ANALYSIS OF THE PHARMACEUTICALS MARKET

6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 5 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • 6.2 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS
    • 6.2.1 GROWING NUMBER OF NEW MOLECULAR ENTITIES GAINING REGULATORY APPROVALS TO DRIVE MARKET GROWTH
    • TABLE 6 INDICATIVE LIST OF BIOLOGICAL PRODUCTS THAT GAINED US FDA APPROVAL IN 2019
    • TABLE 7 LIST OF MAJOR DRUGS SET TO LOSE PATENT PROTECTION IN 2020
    • TABLE 8 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 9 NORTH AMERICA: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 10 EUROPE: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 11 ASIA: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
  • 6.3 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS
    • 6.3.1 GOVERNMENT INITIATIVES SUPPORTING THE ADOPTION OF GENERIC DRUGS TO BOOST MARKET GROWTH
    • TABLE 12 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 13 NORTH AMERICA: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 14 EUROPE: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 15 ASIA: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)

7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER

  • 7.1 INTRODUCTION
    • TABLE 16 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
  • 7.2 CAPTIVE API MANUFACTURERS
    • 7.2.1 HIGH MANUFACTURING FLEXIBILITY AND ASSURANCE OF PRODUCT QUALITY ARE THE KEY FACTORS SUPPORTING MARKET GROWTH
    • TABLE 17 CAPTIVE API MANUFACTURERS MARKET, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 18 NORTH AMERICA: CAPTIVE API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 19 EUROPE: CAPTIVE API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 20 ASIA: CAPTIVE API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
  • 7.3 MERCHANT API MANUFACTURERS
    • TABLE 21 MERCHANT API MANUFACTURERS MARKET, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 22 NORTH AMERICA: MERCHANT API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 23 EUROPE: MERCHANT API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 24 ASIA: MERCHANT API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • 7.3.1 MERCHANT API MANUFACTURERS MARKET, BY TYPE
    • TABLE 25 MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
      • 7.3.1.1 Innovative API manufacturers
        • 7.3.1.1.1 Impending patent expiries and increasing costs of innovative drugs may restrain the market growth
    • TABLE 26 INNOVATIVE API MANUFACTURERS MARKET, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 27 NORTH AMERICA: INNOVATIVE API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 28 EUROPE: INNOVATIVE API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 29 ASIA: INNOVATIVE API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
      • 7.3.1.2 Generic API manufacturers
        • 7.3.1.2.1 Low manufacturing cost of generics will drive the growth of this segment
    • TABLE 30 GENERIC API MANUFACTURERS MARKET, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 31 NORTH AMERICA: GENERIC API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 32 EUROPE: GENERIC API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 33 ASIA: GENERIC API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • 7.3.2 MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS
    • TABLE 34 MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS 2018-2025 (USD BILLION)
      • 7.3.2.1 Synthetic API manufacturers
        • 7.3.2.1.1 Need for specialized manufacturing capabilities is driving the growth of this segment
    • TABLE 35 SYNTHETIC API MANUFACTURERS MARKET, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 36 NORTH AMERICA: SYNTHETIC API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 37 EUROPE: SYNTHETIC API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 38 ASIA: SYNTHETIC API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
      • 7.3.2.2 Biotech API manufacturers
        • 7.3.2.2.1 Complexity of manufacturing biotech APIs has increased the focus on partnerships between companies and CMOs
    • TABLE 39 BIOTECH API MANUFACTURERS MARKET, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 40 NORTH AMERICA: BIOTECH API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 41 EUROPE: BIOTECH API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 42 ASIA: BIOTECH API MANUFACTURERS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)

8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS

  • 8.1 INTRODUCTION
    • TABLE 43 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
  • 8.2 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS
    • TABLE 44 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 45 NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 46 EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 47 ASIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • 8.2.1 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
    • TABLE 48 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
      • 8.2.1.1 Innovative synthetic APIs
        • 8.2.1.1.1 High value of innovative APIs to drive the growth of this segment
    • TABLE 49 INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 50 NORTH AMERICA: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 51 EUROPE: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 52 ASIA: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
      • 8.2.1.2 Generic synthetic APIs
        • 8.2.1.2.1 Initiatives to promote the penetration of generics will drive the growth of this segment
    • TABLE 53 GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 54 NORTH AMERICA: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 55 EUROPE: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 56 ASIA: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
  • 8.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS
    • TABLE 57 TOP SELLING BIOLOGICS (2018)
    • TABLE 58 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 59 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 60 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 61 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • 8.3.1 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
    • TABLE 62 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
      • 8.3.1.1 Innovative biotech APIs
        • 8.3.1.1.1 Growing demand for innovative biopharmaceuticals to drive the growth of this segment
    • TABLE 63 INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 64 NORTH AMERICA: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 65 EUROPE: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 66 ASIA: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
      • 8.3.1.2 Generic biotech APIs
        • 8.3.1.2.1 Increasing demand for biosimilar drugs due to their cost-effectiveness to drive the growth of this segment
    • TABLE 67 INDICATIVE LIST OF BIOSIMILARS THAT GAINED THE US FDA APPROVAL IN 2019
    • TABLE 68 GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 69 NORTH AMERICA: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 70 EUROPE: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 71 ASIA: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • 8.3.2 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT
    • TABLE 72 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT 2018-2025 (USD BILLION)
      • 8.3.2.1 Monoclonal antibodies
        • 8.3.2.1.1 Growing applications of antibody-drug conjugates in the treatment of cancer to drive the growth of this segment
    • TABLE 73 INDICATIVE LIST OF MONOCLONAL ANTIBODIES THAT RECEIVED FDA APPROVAL IN 2019
    • TABLE 74 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 75 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 76 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 77 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2025 (USD BILLION)
      • 8.3.2.2 Hormones & growth factors
        • 8.3.2.2.1 The growing incidence of hormonal disorders will drive market growth
    • TABLE 78 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 79 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 80 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 81 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2018-2025 (USD BILLION)
      • 8.3.2.3 Cytokines
        • 8.3.2.3.1 Interferons and interleukins boost the immune system and have important applications in cancer treatment
    • TABLE 82 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 83 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 84 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 85 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2018-2025 (USD BILLION)
      • 8.3.2.4 Fusion proteins
        • 8.3.2.4.1 Growing applications of fusion proteins in biopharmaceuticals to drive the growth of this segment
    • TABLE 86 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 87 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 88 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 89 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2018-2025 (USD BILLION)
      • 8.3.2.5 Recombinant vaccines
        • 8.3.2.5.1 Growing prevalence of infectious diseases has boosted vaccine development-a positive indicator of growth
    • TABLE 90 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 91 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 92 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 93 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2018-2025 (USD BILLION)
      • 8.3.2.6 Therapeutic enzymes
        • 8.3.2.6.1 Growing significance of enzymes in therapies for cancer and pain management will drive the growth of this segment
    • TABLE 94 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 95 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 96 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 97 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2018-2025 (USD BILLION)
      • 8.3.2.7 Blood factors
        • 8.3.2.7.1 Growing incidence of hemophilia to drive the growth of this segment
    • TABLE 98 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 99 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 100 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 101 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY COUNTRY, 2018-2025 (USD BILLION)
    • 8.3.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM
    • TABLE 102 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
      • 8.3.3.1 Mammalian expression systems
        • 8.3.3.1.1 Their ability to carry post-translational modifications will drive the market for these systems
    • TABLE 103 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 104 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 105 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 106 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)
      • 8.3.3.2 Microbial expression systems
        • 8.3.3.2.1 These systems provide high expression levels of proteins, which supports their use
    • TABLE 107 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 108 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 109 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 110 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)
      • 8.3.3.3 Yeast expression systems
        • 8.3.3.3.1 Advantages such as efficient protein secretion, simple purification, and endotoxin-free products to boost demand
    • TABLE 111 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 112 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 113 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 114 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)
      • 8.3.3.4 Insect expression systems
        • 8.3.3.4.1 Efficient post-translational modifications provided by these systems to boost their demand
    • TABLE 115 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 116 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 117 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 118 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)
      • 8.3.3.5 Other expression systems
    • TABLE 119 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 120 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 121 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 122 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2018-2025 (USD BILLION)

9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG

  • 9.1 INTRODUCTION
    • TABLE 123 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
  • 9.2 PRESCRIPTION DRUGS
    • 9.2.1 GROWING DISEASE PREVALENCE IS EXPECTED TO DRIVE THE PRESCRIPTION DRUGS MARKET
    • TABLE 124 PRESCRIPTION DRUGS MARKET, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 125 NORTH AMERICA: PRESCRIPTION DRUGS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 126 EUROPE: PRESCRIPTION DRUGS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 127 ASIA: PRESCRIPTION DRUGS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
  • 9.3 OVER-THE-COUNTER DRUGS
    • 9.3.1 SALES OF OTC DRUGS HAVE RISEN DUE TO INNOVATIONS, PROMOTION OF SELF-MEDICATION, AND INCREASED ACCESS
    • TABLE 128 OVER-THE-COUNTER DRUGS MARKET, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 129 NORTH AMERICA: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 130 EUROPE: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 131 ASIA: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
  • 9.4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY
    • 9.4.1 LOW-TO-MODERATE-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS
      • 9.4.1.1 Higher safety, good warning properties, and lack of genic effects characterize low-to-moderate-potency APIs
    • 9.4.2 POTENT-TO-HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS
      • 9.4.2.1 Most drugs under development fall into this category
    • TABLE 132 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)

10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION

  • 10.1 INTRODUCTION
    • TABLE 133 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
  • 10.2 COMMUNICABLE DISEASES
    • 10.2.1 INCREASING GLOBAL INCIDENCE OF COMMUNICABLE DISEASES TO DRIVE MARKET GROWTH
    • TABLE 134 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 135 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 136 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 137 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2018-2025 (USD BILLION)
  • 10.3 ONCOLOGY
    • 10.3.1 INCREASING SPENDING ON CANCER MEDICATION TO SUPPORT THE GROWTH OF THIS SEGMENT
    • TABLE 138 INDICATIVE LIST OF THE US FDA-APPROVED DRUGS FOR ONCOLOGY (2018)
    • TABLE 139 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 140 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 141 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 142 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2018-2025 (USD BILLION)
  • 10.4 DIABETES
    • 10.4.1 HIGH GLOBAL PREVALENCE OF DIABETES TO DRIVE THE GROWTH OF THIS SEGMENT
    • TABLE 143 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 144 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 145 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 146 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2018-2025 (USD BILLION)
  • 10.5 CARDIOVASCULAR DISEASES
    • 10.5.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES OWING TO SEDENTARY LIFESTYLES IS A MAJOR GROWTH DRIVER
    • TABLE 147 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 148 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 149 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 150 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2025 (USD BILLION)
  • 10.6 PAIN MANAGEMENT
    • 10.6.1 INCREASING DEMAND FOR INNOVATIVE AND ADVANCED PAIN MEDICATIONS IS A MAJOR GROWTH DRIVER FOR THIS MARKET
    • TABLE 151 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 152 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 153 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 154 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2018-2025 (USD BILLION)
  • 10.7 RESPIRATORY DISEASES
    • 10.7.1 HIGH GLOBAL PREVALENCE OF RESPIRATORY DISEASES TO DRIVE THE GROWTH OF THIS SEGMENT
    • TABLE 155 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 156 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 157 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 158 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2018-2025 (USD BILLION)
  • 10.8 OTHER THERAPEUTIC APPLICATIONS
    • TABLE 159 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2018-2025 (USD BILLION)
    • TABLE 160 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 161 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 162 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2018-2025 (USD BILLION)

11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 163 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2018-2025 (USD BILLION)
  • 11.2 NORTH AMERICA
    • FIGURE 19 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT
    • TABLE 164 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 165 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 166 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
    • TABLE 167 NORTH AMERICA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 168 NORTH AMERICA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 169 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 170 NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 171 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 172 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
    • TABLE 173 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
    • TABLE 174 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
    • TABLE 175 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
    • TABLE 176 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
    • 11.2.1 US
      • 11.2.1.1 The US is the largest market for active pharmaceutical ingredients in North America
    • TABLE 177 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 178 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
    • TABLE 179 US: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 180 US: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 181 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 182 US: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 183 US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 184 US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
    • TABLE 185 US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
    • TABLE 186 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
    • TABLE 187 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
    • TABLE 188 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION) 182
    • 11.2.2 CANADA
      • 11.2.2.1 Support from government organizations is driving the growth of the APIs market in Canada
    • TABLE 189 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 190 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
    • TABLE 191 CANADA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 192 CANADA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 193 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 194 CANADA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 195 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 196 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
    • TABLE 197 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
    • TABLE 198 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
    • TABLE 199 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
    • TABLE 200 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
  • 11.3 EUROPE
    • TABLE 201 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 202 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 203 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
    • TABLE 204 EUROPE: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 205 EUROPE: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 206 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 207 EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 208 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 209 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
    • TABLE 210 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
    • TABLE 211 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
    • TABLE 212 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
    • TABLE 213 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
    • 11.3.1 GERMANY
      • 11.3.1.1 Germany dominates the European active pharmaceutical ingredients market
    • TABLE 214 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 215 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
    • TABLE 216 GERMANY: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 217 GERMANY: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 218 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 219 GERMANY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 220 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 221 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
    • TABLE 222 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
    • TABLE 223 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
    • TABLE 224 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
    • TABLE 225 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
    • 11.3.2 FRANCE
      • 11.3.2.1 An increase in annual pharmaceutical industry turnover will support market growth in France
    • TABLE 226 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 227 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
    • TABLE 228 FRANCE: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 229 FRANCE: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 230 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 231 FRANCE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 232 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 233 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
    • TABLE 234 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
    • TABLE 235 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
    • TABLE 236 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
    • TABLE 237 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
    • 11.3.3 UK
      • 11.3.3.1 Rising government investments will drive the growth of the UK market
    • TABLE 238 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 239 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
    • TABLE 240 UK: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 241 UK: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 242 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 243 UK: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 244 UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 245 UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
    • TABLE 246 UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
    • TABLE 247 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
    • TABLE 248 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
    • TABLE 249 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
    • 11.3.4 ITALY
      • 11.3.4.1 Growing investment in API production will support market growth
    • TABLE 250 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 251 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
    • TABLE 252 ITALY: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 253 ITALY: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 254 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 255 ITALY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 256 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 257 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
    • TABLE 258 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
    • TABLE 259 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
    • TABLE 260 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
    • TABLE 261 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
    • 11.3.5 SPAIN
      • 11.3.5.1 The Spanish market has been typically dominated by branded drugs
    • TABLE 262 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 263 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
    • TABLE 264 SPAIN: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 265 SPAIN: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 266 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 267 SPAIN: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 268 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 269 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
    • TABLE 270 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
    • TABLE 271 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
    • TABLE 272 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
    • TABLE 273 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
    • 11.3.6 HUNGARY
      • 11.3.6.1 Rising incidence of chronic diseases will contribute to market growth
    • TABLE 274 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 275 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
    • TABLE 276 HUNGARY: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 277 HUNGARY: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 278 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 279 HUNGARY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 280 HUNGARY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 281 HUNGARY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
    • TABLE 282 HUNGARY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
    • TABLE 283 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
    • TABLE 284 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
    • TABLE 285 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
    • 11.3.7 REST OF EUROPE
    • TABLE 286 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 287 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
    • TABLE 288 ROE: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 289 ROE: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 290 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 291 ROE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 292 ROE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 293 ROE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
    • TABLE 294 ROE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
    • TABLE 295 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
    • TABLE 296 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
    • TABLE 297 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
  • 11.4 ASIA
    • FIGURE 20 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT
    • TABLE 298 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 299 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 300 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
    • TABLE 301 ASIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 302 ASIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 303 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 304 ASIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 305 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 306 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
    • TABLE 307 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
    • TABLE 308 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
    • TABLE 309 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
    • TABLE 310 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
    • 11.4.1 JAPAN
      • 11.4.1.1 Japan dominates the Asian market for APIs
    • TABLE 311 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 312 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
    • TABLE 313 JAPAN: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 314 JAPAN: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 315 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 316 JAPAN: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 317 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 318 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
    • TABLE 319 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
    • TABLE 320 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
    • TABLE 321 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025(USD BILLION)
    • TABLE 322 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
    • 11.4.2 CHINA
      • 11.4.2.1 Government policies to increase medicine access and affordability will support market growth
    • TABLE 323 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 324 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
    • TABLE 325 CHINA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 326 CHINA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 327 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 328 CHINA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 329 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 330 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
    • TABLE 331 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
    • TABLE 332 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
    • TABLE 333 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
    • TABLE 334 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
    • 11.4.3 INDIA
      • 11.4.3.1 India is a leading producer of generics
    • TABLE 335 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 336 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
    • TABLE 337 INDIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 338 INDIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 339 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 340 INDIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 341 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 342 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
    • TABLE 343 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
    • TABLE 344 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
    • TABLE 345 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
    • TABLE 346 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
    • 11.4.4 SOUTH KOREA
      • 11.4.4.1 Rising annual drug exports are likely to drive market growth
    • TABLE 347 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 348 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
    • TABLE 349 SOUTH KOREA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 350 SOUTH KOREA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 351 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 352 SOUTH KOREA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 353 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 354 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
    • TABLE 355 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
    • TABLE 356 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
    • TABLE 357 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
    • TABLE 358 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
    • 11.4.5 REST OF ASIA
    • TABLE 359 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 360 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
    • TABLE 361 ROA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 362 ROA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 363 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 364 ROA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 365 ROA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 366 ROA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
    • TABLE 367 ROA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
    • TABLE 368 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
    • TABLE 369 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
    • TABLE 370 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
  • 11.5 REST OF THE WORLD
    • TABLE 371 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
    • TABLE 372 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 373 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
    • TABLE 374 ROW: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 375 ROW: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 376 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 377 ROW: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 378 ROW: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 379 ROW: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
    • TABLE 380 ROW: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
    • TABLE 381 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
    • TABLE 382 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
    • TABLE 383 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
    • 11.5.1 ISRAEL
      • 11.5.1.1 Financial support by the government will drive market growth
    • TABLE 384 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 385 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
    • TABLE 386 ISRAEL: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 387 ISRAEL: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 388 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 389 ISRAEL: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 390 ISRAEL: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 391 ISRAEL: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
    • TABLE 392 ISRAEL: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
    • TABLE 393 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
    • TABLE 394 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
    • TABLE 395 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)
    • 11.5.2 OTHER COUNTRIES
    • TABLE 396 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 397 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018-2025 (USD BILLION)
    • TABLE 398 OTHER COUNTRIES: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 399 OTHER COUNTRIES: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 400 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018-2025 (USD BILLION)
    • TABLE 401 OTHER COUNTRIES: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 402 OTHER COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018-2025 (USD BILLION)
    • TABLE 403 OTHER COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018-2025 (USD BILLION)
    • TABLE 404 OTHER COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018-2025 (USD BILLION)
    • TABLE 405 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018-2025 (USD BILLION)
    • TABLE 406 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018-2025 (USD BILLION)
    • TABLE 407 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018-2025 (USD BILLION)

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 MARKET EVALUATION FRAMEWORK
    • TABLE 408 GROWTH STRATEGY MATRIX: EXPANSIONS AND COLLABORATIONS ARE THE WIDELY ADOPTED GROWTH STRATEGIES BY MARKET PLAYERS
  • 12.3 COMPETITIVE SITUATION AND TRENDS
    • TABLE 409 PRODUCT LAUNCHES, JANUARY 2017-AUGUST 2020
    • TABLE 410 EXPANSIONS, JANUARY 2017-AUGUST 2020
    • TABLE 411 ACQUISITIONS, JANUARY 2017-AUGUST 2020
    • TABLE 412 AGREEMENTS, COLLABORATIONS, ALLIANCES, JOINT VENTURES, AND PARTNERSHIPS, JANUARY 2017-AUGUST 2020

13 COMPANY EVALUATION MATRIX AND COMPANY PROFILES

  • 13.1 COMPANY EVALUATION MATRIX DEFINITION AND METHODOLOGY
  • 13.2 COMPANY EVALUATION MATRIX
    • 13.2.1 STARS
    • 13.2.2 EMERGING LEADERS
    • 13.2.3 PERVASIVE PLAYERS
    • 13.2.4 EMERGING COMPANIES
    • FIGURE 21 COMPETITIVE LEADERSHIP MAPPING OF THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET - OVERALL MARKET
  • 13.3 COMPETITIVE LEADERSHIP MAPPING - START-UPS/SMES
    • 13.3.1 PROGRESSIVE COMPANIES
    • 13.3.2 STARTING BLOCKS
    • 13.3.3 RESPONSIVE COMPANIES
    • 13.3.4 DYNAMIC COMPANIES
    • FIGURE 22 COMPETITIVE LEADERSHIP MAPPING OF THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET - START-UPS/SMES
  • 13.4 MARKET PLAYER RANKING
    • FIGURE 23 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET PLAYER RANKING, 2019
  • 13.5 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, MnM View)**

    • 13.5.1 PFIZER, INC.
    • FIGURE 24 PFIZER, INC.: COMPANY SNAPSHOT (2019)
    • 13.5.2 NOVARTIS AG
    • FIGURE 25 NOVARTIS AG: COMPANY SNAPSHOT (2019)
    • 13.5.3 SANOFI
    • FIGURE 26 SANOFI: COMPANY SNAPSHOT (2019)
    • 13.5.4 BOEHRINGER INGELHEIM
    • FIGURE 27 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2019)
    • 13.5.5 BRISTOL-MYERS SQUIBB
    • FIGURE 28 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2019)
    • 13.5.6 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • FIGURE 29 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2019)
    • 13.5.7 ELI LILLY AND COMPANY
    • FIGURE 30 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2019)
    • 13.5.8 GLAXOSMITHKLINE PLC
    • FIGURE 31 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2019)
    • 13.5.9 MERCK & CO., INC.
    • FIGURE 32 MERCK & CO., INC.: COMPANY SNAPSHOT (2019)
    • 13.5.10 MYLAN N.V.
    • FIGURE 33 MYLAN N.V.: COMPANY SNAPSHOT (2019)
    • 13.5.11 ABBVIE INC.
    • FIGURE 34 ABBVIE INC.: COMPANY SNAPSHOT (2019)
    • 13.5.12 F. HOFFMANN-LA ROCHE LTD.
    • FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2019)
    • 13.5.13 ASTRAZENECA
    • FIGURE 36 ASTRAZENECA: COMPANY SNAPSHOT (2019)
    • 13.5.14 DR. REDDY'S LABORATORIES LTD.
    • FIGURE 37 DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT (2019)
    • 13.5.15 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • FIGURE 38 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2019)
    • 13.5.16 CIPLA, INC.
    • FIGURE 39 CIPLA, INC.: COMPANY SNAPSHOT (2019)
    • 13.5.17 API PHARMA TECH
    • 13.5.18 BDR PHARMACEUTICALS INTERNATIONALS PVT. LTD.
    • 13.5.19 SREEPATHI PHARMACEUTICALS LIMITED
    • 13.5.20 SHILPA MEDICARE LIMITED

*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 AVAILABLE CUSTOMIZATIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS 337